Anti-HBV antiviral prophylaxis
Phase 3Small molecule
Anti-HBV antiviral prophylaxis is one of 36 small molecule programs targeting Hepatitis B. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
44 competitors in Hepatitis B
#DrugCompanyPhaseTrials
1Vemlidy
GileadApproved
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Emtriva
GileadApproved
Selzentry
GSKApproved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Sunlenca
GileadApproved
Cabenuva
GSKApproved
Sustiva
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Retrovir
BBp Consulting, Inc
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatitis B1 trial
Antiviral Prophylaxis and Infant Vaccination to Prevent Perinatal Hepatitis B Infection
Active, not recruiting·IInstitut de Recherche pour le Developpement·Phase 3·NCT03343431·504 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details